Every 10-Q that CDT Equity Inc. (CDT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDT filings page.
CDT Equity Inc. reported a net loss of $8.7 million for the six months ended June 30, 2026, compared with a $10.8 million loss a year earlier, as operating expenses declined, particularly research and development. Cash and cash equivalents were $0.7 million, and operating cash outflow improved to $2.4 million from $6.5 million.
Total assets rose sharply to $126.7 million, driven by a new $122.8 million equity method investment in related-party Sarborg Limited, while current liabilities increased to $23.4 million, including an accrued litigation liability of $9.6 million and an $8.0 million investment payable tied to the Sarborg deal. Stockholders’ equity swung from a $7.2 million deficit at year-end 2025 to $103.1 million of equity, largely due to this investment and substantial warrant issuance and exercises.
The company discloses substantial doubt about its ability to continue as a going concern, citing recurring losses, low cash, and expected future negative cash flows. Management plans to rely on its at-the-market offering program, with approximately $73.6 million of capacity referenced, and a senior secured $2.0 million J.J. Astor convertible note (later amended) plus an equity line of credit, but notes there is no assurance that sufficient funding will be available.
CDT Equity Inc., a data-driven pharmaceutical development company, reported a first‑quarter 2026 net loss of approximately $4.1 million, slightly improved from 2025, on operating expenses of $3.7 million. Research and development was $0.8 million and general and administrative expenses were $2.9 million for the three months ended March 31, 2026.
The balance sheet changed markedly after a 20% equity investment in Sarborg, recorded at $123.0 million and carried at $122.9 million as of March 31, 2026. This drove total assets to $127.1 million and additional paid‑in capital to $177.6 million. Shares outstanding increased to 4,722,457, largely from warrant exercises and stock issued for services and investments.
Liquidity remains strained. As of March 31, 2026, cash and cash equivalents were $0.1 million, with cash used in operating activities of $1.9 million. Management discloses that these factors, despite access to an at‑the‑market program and a $25 million equity line, raise substantial doubt about the company’s ability to continue as a going concern. The company also carries a $9.6 million litigation liability related to the Strand judgment and is involved in additional intellectual property proceedings.
CDT Equity Inc. filed its quarterly report for September 30, 2025. The company reported a net loss of $7.1 million for the quarter and $17.9 million for the nine months. Operating cash outflow was $10.9 million year‑to‑date, while cash and cash equivalents rose to $3.8 million from $0.6 million at year‑end, primarily from equity sales.
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern. The company plans to seek additional financing and noted its remaining at‑the‑market capacity of approximately $1.8 million was utilized after quarter‑end.
Stockholders’ equity improved to $4.3 million from a deficit, as additional paid‑in capital increased to $51.1 million. Convertible notes carried at fair value declined to $1.7 million from $5.9 million, reflecting conversions, repayments, and fair value changes; the company also recorded a $0.4 million waiver of accrued interest. CDT held $1.0 million of Bitcoin (8.65 BTC) as of quarter‑end. Shares outstanding were 1,276,574 as of September 30, 2025, and 1,629,402 as of November 13, 2025.
Conduit Pharmaceuticals (CDT) reported cash and cash equivalents of $3.3 million at June 30, 2025, up from $0.6 million at December 31, 2024. For the six months ended June 30, 2025 the company recorded a net loss of $10.8 million (vs. $8.9 million a year earlier) and used $6.5 million in operating cash (vs. $3.9 million). Management states there is substantial doubt about the company’s ability to continue without raising additional equity or debt financing. The filing discloses two reverse stock splits (1-for-100 in January and 1-for-15 in May 2025), outstanding convertible instruments and warrants, and multiple financings and settlements during the period including repayment and extinguishment gains/losses on certain notes. The Board authorized a $1.0 million open repurchase program and the company repurchased 11,713 shares at an average price of $8.85 per share.
Conduit Pharmaceuticals, Inc. (CDT) amended its Quarterly Report. The company reported cash and cash equivalents of $2.1 million at March 31, 2025, up from $0.6 million at December 31, 2024. For the three months ended March 31, 2025, net loss was $4.8 million compared with $3.6 million a year earlier, and cash used in operating activities was $3.9 million versus $2.4 million prior-year.
The filing discloses a 1-for-100 reverse stock split effective January 25, 2025, restatements that adjusted prior-period balances, material outstanding convertible obligations (A.G.P. note with approximately $5.5 million principal and interest remaining) and a deferred commission payable of $5.7 million. Management states substantial doubt about the company’s ability to continue as a going concern and plans to pursue additional equity or debt financing, without assurance of success.